Related Experiment Videos
Levamisole as an immunopotentiator for T cell deficiency
1Department of Pediatrics, Medical College of Ohio, Toledo.
Immunopharmacology and Immunotoxicology
|May 1, 1994
Summary
Levamisole restored T cell functions in a child with T cell leukemia and disseminated mycobacterial infection. This immunomodulatory drug successfully treated the severe infection by enhancing cellular immunity.
Area of Science:
- Immunology
- Pharmacology
- Infectious Diseases
Background:
- Levamisole is an antihelminthic with known immunomodulatory effects, including restoring cutaneous delayed hypersensitivity and enhancing T lymphocyte activation.
- It is approved in combination with 5-Fluorouracil for colon cancer treatment.
- Cellular immune deficiencies can lead to severe opportunistic infections, particularly in immunocompromised patients like those undergoing chemotherapy.
Observation:
- A 5 1/2-year-old male presented with a severe, disseminated mycobacterial joint infection.
- This infection was secondary to a deficiency in cellular mediated immunity, exacerbated by chemotherapy for T cell leukemia.
Findings:
- The patient was treated with Levamisole.
- Treatment with Levamisole resulted in the restoration of the patient's T cell functions.
- The mycobacterial infection resolved following Levamisole treatment.
Implications:
- Levamisole demonstrates potential as an effective therapeutic agent for managing severe mycobacterial infections in immunocompromised patients.
- Restoration of cellular immunity via Levamisole can lead to resolution of opportunistic infections.
- This case highlights the utility of immunomodulatory drugs in pediatric oncology and infectious disease management.